174 related articles for article (PubMed ID: 35142162)
1. EGFR/PI3K/Akt/mTOR pathway in head and neck squamous cell carcinoma patients with different HPV status.
Janecka-Widła A; Majchrzyk K; Mucha-Małecka A; Biesaga B
Pol J Pathol; 2021; 72(4):296-314. PubMed ID: 35142162
[TBL] [Abstract][Full Text] [Related]
2. Prognostic potential of Akt, pAkt(Ser473) and pAkt(Thr308) immunoreactivity in relation to HPV prevalence in head and neck squamous cell carcinoma patients.
Janecka-Widła A; Majchrzyk K; Mucha-Małecka A; Słonina D; Biesaga B
Pathol Res Pract; 2022 Jan; 229():153684. PubMed ID: 34839095
[TBL] [Abstract][Full Text] [Related]
3. PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer.
Marquard FE; Jücker M
Biochem Pharmacol; 2020 Feb; 172():113729. PubMed ID: 31785230
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of pAKT(Ser473) expression in progression of HPV-positive oropharyngeal squamous cell carcinoma.
Horn D; Freudlsperger C; Holzinger D; Kunzmann K; Plinkert P; Dyckhoff G; Hoffmann J; Freier K; Hess J
Head Neck; 2017 Dec; 39(12):2397-2405. PubMed ID: 28945300
[TBL] [Abstract][Full Text] [Related]
5. p-mTOR, p-ERK and PTEN Expression in Tumor Biopsies and Organoids as Predictive Biomarkers for Patients with HPV Negative Head and Neck Cancer.
de Kort WWB; de Ruiter EJ; Haakma WE; Driehuis E; Devriese LA; van Es RJJ; Willems SM
Head Neck Pathol; 2023 Sep; 17(3):697-707. PubMed ID: 37486536
[TBL] [Abstract][Full Text] [Related]
6. Difference in expression of EGFR, pAkt, and PTEN between oropharyngeal and oral cavity squamous cell carcinoma.
Won HS; Jung CK; Chun SH; Kang JH; Kim YS; Sun DI; Kim MS
Oral Oncol; 2012 Oct; 48(10):985-990. PubMed ID: 22682934
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic strategies of different HPV status in Head and Neck Squamous Cell Carcinoma.
Sun Y; Wang Z; Qiu S; Wang R
Int J Biol Sci; 2021; 17(4):1104-1118. PubMed ID: 33867833
[TBL] [Abstract][Full Text] [Related]
8. Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma.
Horn D; Hess J; Freier K; Hoffmann J; Freudlsperger C
Expert Opin Ther Targets; 2015 Jun; 19(6):795-805. PubMed ID: 25652792
[TBL] [Abstract][Full Text] [Related]
9. Molecular profile of head and neck squamous cell carcinomas bearing p16 high phenotype.
Rampias T; Pectasides E; Prasad M; Sasaki C; Gouveris P; Dimou A; Kountourakis P; Perisanidis C; Burtness B; Zaramboukas T; Rimm D; Fountzilas G; Psyrri A
Ann Oncol; 2013 Aug; 24(8):2124-31. PubMed ID: 23406730
[TBL] [Abstract][Full Text] [Related]
10. Expression profile of the PI3K-AKT-mTOR pathway in head and neck squamous cell carcinoma: Data from Brazilian population.
Marques AEM; Borges GA; Viesi do Nascimento Filho CH; Vianna LMS; Ramos DDAR; Castilho RM; Squarize CH; Guerra ENS
Oral Surg Oral Med Oral Pathol Oral Radiol; 2022 Apr; 133(4):453-461. PubMed ID: 35153184
[TBL] [Abstract][Full Text] [Related]
11. Divergence of P53, PTEN, PI3K, Akt and mTOR expression in tonsillar cancer.
Chun SH; Jung CK; Won HS; Kang JH; Kim YS; Kim MS
Head Neck; 2015 May; 37(5):636-43. PubMed ID: 24616007
[TBL] [Abstract][Full Text] [Related]
12. Reverse-phase protein array profiling of oropharyngeal cancer and significance of PIK3CA mutations in HPV-associated head and neck cancer.
Sewell A; Brown B; Biktasova A; Mills GB; Lu Y; Tyson DR; Issaeva N; Yarbrough WG
Clin Cancer Res; 2014 May; 20(9):2300-11. PubMed ID: 24599934
[TBL] [Abstract][Full Text] [Related]
13. The PI3K/Akt/mTORC signaling axis in head and neck squamous cell carcinoma: Possibilities for therapeutic interventions either as single agents or in combination with conventional therapies.
Akbari Dilmaghani N; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Bashash D
IUBMB Life; 2021 Apr; 73(4):618-642. PubMed ID: 33476088
[TBL] [Abstract][Full Text] [Related]
14. Differential modulation of PI3K/Akt/mTOR activity by EGFR inhibitors: A rationale for co-targeting EGFR and PI3K in cisplatin-resistant HNSCC.
Liao J; Yang Z; Azarbarzin S; Cullen KJ; Dan H
Head Neck; 2024 May; 46(5):1126-1135. PubMed ID: 38429897
[TBL] [Abstract][Full Text] [Related]
15. EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy.
Freudlsperger C; Burnett JR; Friedman JA; Kannabiran VR; Chen Z; Van Waes C
Expert Opin Ther Targets; 2011 Jan; 15(1):63-74. PubMed ID: 21110697
[TBL] [Abstract][Full Text] [Related]
16. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
17. Simultaneously targeting ErbB family kinases and PI3K in HPV-positive head and neck squamous cell carcinoma.
Yang Z; Liao J; Schumaker L; Carter-Cooper B; Lapidus RG; Fan X; Gaykalova DA; Mehra R; Cullen KJ; Dan H
Oral Oncol; 2022 Aug; 131():105939. PubMed ID: 35667295
[TBL] [Abstract][Full Text] [Related]
18. PI3K/AKT/mTOR Signaling Regulates the Virus/Host Cell Crosstalk in HPV-Positive Cervical Cancer Cells.
Bossler F; Hoppe-Seyler K; Hoppe-Seyler F
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31058807
[TBL] [Abstract][Full Text] [Related]
19. [Relationship between human papilloma virus infection and expression of p16 and EGFR in head and neck squamous cell carcinoma and their prognostic significance].
Ma L; Wang D; Wufuer A; Wu R; Zhang S; Wang R
Zhonghua Zhong Liu Za Zhi; 2014 Jan; 36(1):23-8. PubMed ID: 24685082
[TBL] [Abstract][Full Text] [Related]
20. Absence of human papillomavirus infection and activation of PI3K-AKT pathway in cervical clear cell carcinoma.
Ueno S; Sudo T; Oka N; Wakahashi S; Yamaguchi S; Fujiwara K; Mikami Y; Nishimura R
Int J Gynecol Cancer; 2013 Jul; 23(6):1084-91. PubMed ID: 23792604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
